BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37467193)

  • 1. Solute carrier family 35 member A2 (SLC35A2) is a prognostic biomarker and correlated with immune infiltration in stomach adenocarcinoma.
    Huang Z; Yang H; Lao J; Deng W
    PLoS One; 2023; 18(7):e0287303. PubMed ID: 37467193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of RFX5 as prognostic biomarker and associated with immune infiltration in stomach adenocarcinoma.
    Guo L; Liu D
    Eur J Med Res; 2022 Aug; 27(1):164. PubMed ID: 36045400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DOCK4 as a Potential Biomarker Associated with Immune Infiltration in Stomach Adenocarcinoma: A Database Analysis.
    Lu Y; Yu J; Dong Q; Du Y; Liang Z
    Int J Gen Med; 2022; 15():6127-6143. PubMed ID: 35846794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value and Immune Infiltrates of ABCA8 and FABP4 in Stomach Adenocarcinoma.
    Guo Y; Wang ZW; Su WH; Chen J; Wang YL
    Biomed Res Int; 2020; 2020():4145164. PubMed ID: 32685482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Analysis and Identification of Prognostic Biomarkers and Therapeutic Targets Among FAM83 Family Members for Gastric Cancer.
    Zhang T; Lai S; Cai Y; Huang Z; Li Y; Chen S; Zhang Z; Ye Z; Lai X; Zhai E; Cai S; Chen J
    Front Cell Dev Biol; 2021; 9():719613. PubMed ID: 34869310
    [No Abstract]   [Full Text] [Related]  

  • 8. Comprehensive bioinformatic analysis of mind bomb 1 gene in stomach adenocarcinoma.
    Wang D; Wang QH; Luo T; Jia W; Wang J
    World J Gastrointest Oncol; 2023 Jul; 15(7):1295-1310. PubMed ID: 37546549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IRF7 is a Prognostic Biomarker and Associated with Immune Infiltration in Stomach Adenocarcinoma.
    Guo L; Fang T; Jiang Y; Liu D
    Int J Gen Med; 2021; 14():9887-9902. PubMed ID: 34938108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and role of nuclear receptor-interacting protein 1 (NRIP1) in stomach adenocarcinoma.
    Fang D; Lu G
    Ann Transl Med; 2020 Oct; 8(20):1293. PubMed ID: 33209873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-cancer analysis of the prognostic and immunological role of GJB2: a potential target for survival and immunotherapy.
    Jia Y; Guo B; Zhang W; Wang F; Zhang Y; Zhang Q; Li E
    Front Oncol; 2023; 13():1110207. PubMed ID: 37427102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic and antitumor roles of key genes of ferroptosis in liver hepatocellular cancer and stomach adenocarcinoma.
    Pei W; Jiang M; Liu H; Song J; Hu J
    Cancer Biomark; 2024; 39(4):335-347. PubMed ID: 38393890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy.
    Hu J; Qiu D; Yu A; Hu J; Deng H; Li H; Yi Z; Chen J; Zu X
    Front Oncol; 2021; 11():607224. PubMed ID: 34026603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PLVAP protein expression correlated with microbial composition, clinicopathological features, and prognosis of patients with stomach adenocarcinoma.
    Wen Y; Wang Y; Huang Y; Liu Z; Hui C
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7139-7153. PubMed ID: 36884119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ASF1B acted as a prognostic biomarker for stomach adenocarcinoma.
    Zhao C; Zhou J; Xing J; Yin Q
    Medicine (Baltimore); 2023 Dec; 102(48):e35408. PubMed ID: 38050219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WGCNA identification of TLR7 as a novel diagnostic biomarker, progression and prognostic indicator, and immunotherapeutic target for stomach adenocarcinoma.
    Yuan Q; Zhou Q; Ren J; Wang G; Yin C; Shang D; Xia S
    Cancer Med; 2021 Jun; 10(12):4004-4016. PubMed ID: 33982398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and immunological role of Fam20C in pan-cancer.
    Liu X; Zhan Y; Xu W; Liu X; Geng Y; Liu L; Da J; Wang J; Zhang X; Jin H; Liu Z; Guo S; Zhang B; Li Y
    Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33306121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Expression of the Component 3a Receptor 1 (C3AR1) Gene in Stomach Adenocarcinomas Infers a Poor Prognosis and High Immune-Infiltration Levels.
    Yang H; Li L; Liu X; Zhao Y
    Med Sci Monit; 2021 Feb; 27():e927977. PubMed ID: 33539329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-omics profiling and digital image analysis reveal the potential prognostic and immunotherapeutic properties of CD93 in stomach adenocarcinoma.
    Wu B; Fu L; Guo X; Hu H; Li Y; Shi Y; Zhang Y; Han S; Lv C; Tian Y
    Front Immunol; 2023; 14():984816. PubMed ID: 36761750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIMP2 is associated with prognosis and immune infiltrates of gastric and colon cancer.
    Jian F; Yanhong J; Limeng W; Guoping N; Yiqing T; Hao L; Zhaoji P
    Int Immunopharmacol; 2022 Sep; 110():109008. PubMed ID: 35792273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.